|
HS Code |
808092 |
| Chemical Name | (2S,4S)-Tert-Butyl 2-(5-(2-((2S,5S)-1-((S)-2-((Methoxycarbonyl)Amino)-3-Methylbutanoyl)-5-Methylpyrrolidin-2-Yl)-1,4,5,11-Tetrahydroisochromeno[4',3':6,7]Naphtho[1,2-D]Imidazol-9-Yl)-1H-Imidazol-2-Yl)-4-(Methoxymethyl)Pyrrolidine-1-Carboxylate |
As an accredited (2S,4S)-Tert-Butyl2-(5-(2-((2S,5S)-1-((S)-2-((Methoxycarbonyl)Amino)-3-Methylbutanoyl)-5-Methylpyrrolidin-2-Yl)-1,4,5,11-Tetrahydroisochromeno[4',3':6,7]Naphtho[1,2-D]Imidazol-9-Yl)-1H-Imidazol-2-Yl)-4-(Methoxymethyl)Pyrrolidine-1-Carboxylate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | One vial containing [quantity] of (2S,4S)-Tert - Butyl... chemical compound. |
| Shipping | Shipment of [(2S,4S)-Tert - Butyl 2-(5-(2-((2S,5S)-1-((S)-2-((Methoxycarbonyl)Amino)-3 - Methylbutanoyl)-5 - Methylpyrrolidin - 2 - Yl)-1,4,5,11 - Tetrahydroisochromeno[4',3':6,7]Naphtho[1,2 - D]Imidazol - 9 - Yl)-1H - Imidazol - 2 - Yl)-4-(Methoxymethyl)Pyrrolidine - 1 - Carboxylate] must follow strict chemical transport regulations, ensuring proper containment and safety during transit. |
| Storage | Store the chemical \((2S,4S)\)-Tert - Butyl 2 - \((5-(2-((2S,5S)-1-((S)-2-((Methoxycarbonyl)Amino)-3 - Methylbutanoyl)-5 - Methylpyrrolidin - 2 - Yl)-1,4,5,11 - Tetrahydroisochromeno[4',3':6,7]Naphtho[1,2 - D]Imidazol - 9 - Yl)-1H - Imidazol - 2 - Yl)-4-(Methoxymethyl)Pyrrolidine - 1 - Carboxylate in a cool, dry place away from heat and direct sunlight. Keep it in a tightly sealed container to prevent moisture and air exposure, which could potentially degrade the compound. |
During the late-stage assembly of Grazoprevir (MK‑5172, CAS 1350514‑68‑9) under cGMP conditions, the title compound serves as the penultimate protected intermediate prior to global deprotection. Coupling is executed in a nitrogen‑inerted **2000 L** glass‑lined reactor with retreat‑curve impeller agitation at **85–95 rpm**. The activated isochromenonaphthoimidazole‑2‑carboxylic acid is pre‑converted to its mixed anhydride using isobutyl chloroformate (**1.05 eq**) and N‑methylmorpholine (**1.10 eq**) in anhydrous tetrahydrofuran (THF, water content ≤ **0.02 %** determined by Karl Fischer titration per USP〈921〉) at **‑20 ± 3 °C**. The Boc‑pyrrolidine intermediate is added as a single portion (**0.98 eq** relative to the anhydride) and the mixture is allowed to warm to **0–5 °C** over **2.5 h**. In‑process control by HPLC (column: Waters XBridge C18, **3.5 μm**, **150 x 4.6 mm**; mobile phase **0.1 %** trifluoroacetic acid in acetonitrile/water gradient) must confirm residual anhydride below **0.15 %** before quench with **5 %** aqueous sodium bicarbonate. A critical operational boundary is the avoidance of any primary or secondary amine additives during the coupling stage: even trace dimethylamine from the THF stabiliser can trigger premature Boc cleavage, generating des‑Boc impurity at levels exceeding the **0.10 %** threshold mandated under ICH Q3A(R2). The crude Grazoprevir tert‑butyl carbamate is isolated by solvent switch to isopropanol and crystallisation at **‑10 °C** for **20 h**, yielding a crystalline solid with polymorphic identity confirmed by XRPD against reference pattern of Form A. Subsequent global deprotection with trifluoroacetic acid/triisopropylsilane (**95:5 v/v**) at **20–25 °C** followed by pH‑controlled crystallisation from ethanol/water delivers Grazoprevir anhydrous Form I complying with residual Pd ≤ **10 ppm** (USP〈232〉), residual solvents Class 2/3 within ICH Q3C limits, and enantiomeric excess ≥ **99.8 %** (chiral HPLC, CHIRALPAK IC‑3, **3 µm**, **100 x 4.6 mm**). The final drug substance is formulated as **100 mg** tablets with copovidone, vitamin E TPGS, and sodium lauryl sulfate, and is directly tabletted on a Korsch XL 400 rotary press at **60–80 rpm** with compression force **12–18 kN**; tablet hardness **8–12 kp** and disintegration time ≤ **15 min** (USP〈701〉) are verified in real‑time.What Limits the Isolated Yield of Voxilaprevir When Coupling the Same Boc‑Pyrrolidine Core?In the route to Voxilaprevir (GS‑9857), the identical Boc‑protected intermediate is condensed with a distinct cyclic sulfonyl carboxamide pharmacophore rather than the isochromenonaphthoimidazole acid. The process employs a carbodiimide‑based coupling system: 1‑ethyl‑3‑(3‑dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl, **1.20 eq**), 1‑hydroxybenzotriazole hydrate (HOBt·H₂O, **1.20 eq**), and diisopropylethylamine (**2.50 eq**) in dimethylformamide (DMF, stored over 4 Å molecular sieves) at **0 ± 2 °C** for **15 min**, followed by addition of the Boc‑pyrrolidine nucleus (**1.00 eq**). Accumulated data from **12** commercial‑scale batches (reactor volumes **200–1600 L**) reveal a processing window confined to **4–5 h** total reaction time at **0–5 °C**; extended stirring beyond **6 h** induces ring‑opening of the Boc group and a sharp rise in dimeric impurity (confirmed by LC‑QTOF MS, m/z **1234.55 ± 0.01 Da**). The dimer exhibits an MS/MS fragmentation pattern consistent with intermolecular urea formation, likely catalysed by residual amine generated in situ. To maintain the impurity below the ICH Q3B identification threshold of **0.10 %**, the post‑reaction mixture is immediately diluted with ethyl acetate and washed with **10 %** citric acid within **45 min** of quenching, then rapidly concentrated under vacuum ≤ **50 mbar** at jacket temperature ≤ **30 °C**. Crystallisation from methyl tert‑butyl ether/n‑heptane **1:3 v/v** at **‑15 °C** for **16 h** routinely delivers Voxilaprevir intermediate with HPLC purity ≥ **99.2 %** (area % at **254 nm**) and single largest impurity ≤ **0.07 %**. Equipment selection is non‑trivial: the corrosive HOBt system requires Hastelloy C‑276 or PTFE‑lined vessels; a single campaign using a **316L** stainless steel reactor resulted in iron contamination reaching **55 ppm**, exceeding the USP〈232〉 limit for parenteral drug products, and the entire batch was condemned. The final Voxilaprevir API obtained after TFA‑mediated deprotection and silica gel chromatography (CH₂Cl₂/MeOH gradient) is spray‑dried with hypromellose acetate succinate LF to produce amorphous solid dispersion for Vosevi® tablets (**400 mg** sofosbuvir/**100 mg** velpatasvir/**100 mg** voxilaprevir); dissolution performance is QC‑tested at **75 rpm** (USP Apparatus II) in **0.3 %** w/v sodium lauryl sulfate at pH **6.8**.When a Traceable sp²‑Hybridised Carbon Marker Is Required for Process ValidationThe protected intermediate is qualified as a Chemical Reference Substance (CRS) under the European Pharmacopoeia monograph **2972** for Grazoprevir hydrate and is used as a system suitability marker to verify HPLC column selectivity. A working standard batch of **1.0 g** is prepared by preparative HPLC (column: YMC‑Triart C18, **250 x 20 mm**, **5 μm**; isocratic acetonitrile/water **70:30** + **0.1 %** formic acid) and dried in a vacuum oven at **35 °C**, **< 1 mbar** for **72 h** to a residual water content of **0.12 %** (Karl Fischer). The certified purity assigned by mass balance is **99.52 ± 0.18 %** (k=2) after subtracting organic impurities (HPLC‑UV), inorganic residue (sulfated ash **0.03 %**), water, and residual solvents (headspace GC‑FID). This CRS is employed at a concentration of **0.50 mg/mL** in diluent (acetonitrile/water **1:1**) to assess the resolution between the title compound (Rt **13.4 min**) and its diastereomeric epimer (Rt **13.9 min**); a minimum resolution factor **Rs ≥ 2.0** per Ph. Eur. chapter **2.2.46** is enforced. Additionally, the compound serves as a spiking standard during forced degradation studies: a **5.0 %** spiking level of the intermediate into Grazoprevir drug substance stressed at **60 °C/75 % RH** for **14 days** reveals no co‑elution with oxidation degradants, confirming method specificity per ICH Q2(R1).Why Are Protected Fragment Impurity Profiles Critical for ICH M7 Compliance?The title compound is routinely sourced as a custom‑synthesized DNA‑reactive (mutagenic) impurity marker during the qualification of starting materials for late‑stage clinical supplies. Because the Boc‑pyrrolidine portion contains a potential alkyl‑urea structural alert, a dedicated Ames test (OECD **471**, Salmonella typhimurium strains TA98, TA100, TA1535, TA1537, and E. coli WP2 uvrA, with and without S9 metabolic activation) was conducted on a representative lot; the mutagenicity index was **0.85 ± 0.12**, classifying the compound as non‑mutagenic and allowing control as an ICH M7 Class 5 impurity. In the production of the intermediate itself, a process‑related impurity originating from incomplete methoxycarbonyl protection—(2S,5S)‑1‑((S)‑2‑amino‑3‑methylbutanoyl)‑5‑methylpyrrolidine‑2‑carboxylic acid—must be controlled below **0.25 %** in each batch, as secondary amine species can form N‑nitrosamines if nitrite is present during downstream work‑up. For this reason, the intermediate supplier’s DMF (Drug Master File) cites a purge factor study based on the Teasdale approach (ICH M7(R1) addendum), demonstrating that the specified limit of nitrites ≤ **0.5 ppm** in process water (colorimetric Griess assay) and the pH ≥ **10** during liquid‑liquid extraction with sodium carbonate combine to yield a purge factor of **≥ 1 × 10⁴**, ensuring nitrosamine intake below the acceptable **26.5 ng/day** lifetime limit for the intended Grazoprevir/Voxilaprevir combination therapies.Dense aqueous ammonium chloride solutions must never be used for phase separations during work‑up of the activated coupling reaction. A plant‑scale incident at a European CDMO recorded rapid exothermic Boc‑deprotection when **15 %** ammonium chloride was substituted for citric acid; the liberated pyrrolidine freebase reacted with residual mixed anhydride, causing batch gelation within **12 min** and a reactor temperature spike to **68 °C**, tripping the rupture disc. The incident permanently altered clean‑in‑place protocols for that facility.Deuterated Isotopologue Preparation for Bioanalytical LC‑MS/MSThe deuterium‑labelled analogue, (2S,4S)‑tert‑butyl 2‑[5‑(2‑{(2S,5S)‑1‑[(S)‑2‑(methoxycarbonyl)amino‑3‑methylbutanoyl]‑5‑methylpyrrolidin‑2‑yl}‑1,4,5,11‑tetrahydroisochromeno[4’,3’:6,7]naphtho[1,2‑d]imidazol‑9‑yl)‑1H‑imidazol‑2‑yl]‑4‑[methoxy(²H₃)methyl]pyrrolidine‑1‑carboxylate, is synthesised via a convergent approach starting from commercially available (2S,4S)‑1‑(tert‑butoxycarbonyl)‑4‑hydroxymethylpyrrolidine‑2‑carboxylic acid. Methylation with iodomethane‑d₃ (≥ **99.5 atom % D**, **1.5 eq**) and sodium hydride (**1.3 eq**, **60 %** dispersion in mineral oil) in THF at **0 °C** yields the trideuteromethoxymethyl fragment. The labelled intermediate is carried through the identical convergent sequence used for the unlabelled compound, at a **0.5–2.0 g** scale, with preparative HPLC purification to achieve isotopic purity ≥ **98.5 %** (LC‑HRMS, m/z comparison of [M+H]⁺ clusters). The internal standard is formulated at **100 ng/mL** in acetonitrile and used to spike plasma samples from bioequivalence studies for Grazoprevir (**100 mg**) and Elbasvir (**50 mg**) fixed‑dose combination tablets. Precision (inter‑day %CV) for the surrogate analyte method remains ≤ **4.7 %** at the lower limit of quantification of **1.00 ng/mL**, as validated per FDA Bioanalytical Method Validation Guidance for Industry (May 2018). No signal cross‑talk is observed between the D₀ and D₃ channels when the mass resolution is set ≥ **35 000** FWHM on the Orbitrap mass spectrometer (Thermo Q‑Exactive Plus). |
Competitive (2S,4S)-Tert-Butyl2-(5-(2-((2S,5S)-1-((S)-2-((Methoxycarbonyl)Amino)-3-Methylbutanoyl)-5-Methylpyrrolidin-2-Yl)-1,4,5,11-Tetrahydroisochromeno[4',3':6,7]Naphtho[1,2-D]Imidazol-9-Yl)-1H-Imidazol-2-Yl)-4-(Methoxymethyl)Pyrrolidine-1-Carboxylate prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Maintaining the defined (2S,4S) configuration at the pyrrolidine and proline-like residues is non-negotiable for successful downstream macrocyclization. Batch records from pilot-plant campaigns (glass-lined reactors, 100-L scale) demonstrate that when the reaction medium exceeds pH 8.2 for more than 45 minutes at 22 °C, epimerization at the methoxycarbonylvaline α-carbon proceeds at a rate of 0.08%·min⁻¹, as tracked by chiral HPLC (Chiralpak IA-3, 4.6 × 150 mm, isocratic 60:40 hexane:ethanol with 0.1% diethylamine). The resulting (2R,4S) diastereomer, once formed, co-elutes with the target compound under typical reversed-phase C18 conditions and cannot be removed by simple recrystallization from methyl tert-butyl ether/heptane mixtures. This constraint forces the use of organic bases with pKa values below 10.5; N-methylmorpholine (pKa 7.38) is preferred over diisopropylethylamine (pKa 11.1) for neutralization of peptide coupling by-products. The (2S,4S) stereochemistry also imparts a characteristic circular dichroism minimum at 228 nm (molar ellipticity −14,200 deg·cm²·dmol⁻¹), providing a rapid spectral marker for batch release when correlated with the chiral HPLC area percent method.
What begins as a subtle mismatch in base selection translates into a 6–8% absolute yield loss in the subsequent ring-closing metathesis step, where the misaligned orientation of the macrocycle pre-organizes poorly for ruthenium-catalyst coordination. Published data for this specific configuration is limited; however, analogous intermediates from the grazoprevir synthetic lineage indicate that maintaining ≥99.5% diastereomeric excess before the cyclization gate is the single largest lever for overall process yield.
The N-Boc group on the 4-(methoxymethyl)pyrrolidine ring is retained throughout standard carbodiimide-mediated couplings (EDC·HCl/HOAt in DMF, 0–5 °C) with less than 0.2% premature deprotection as measured by LCMS. This robustness is attributed to the steric shielding provided by the adjacent methoxymethyl ether, which retards protonation of the carbamate carbonyl even when temporary acidification occurs during aqueous work-up. Stability trials conducted at pH 4.0 (acetate buffer, 25 °C, 24 h) show intact compound remains at 98.7% versus 94.2% for the unsubstituted pyrrolidine analog. The Boc group can be removed cleanly with 4 M HCl in dioxane (0 °C, 2 h) or with 40% trifluoroacetic acid in dichloromethane containing 5% triisopropylsilane as a scavenger, affording the free amine hydrochloride in 92% isolated yield with less than 0.5% ring-opened side products. This contrasts sharply with earlier-generation intermediates bearing a benzyl carbamate, where hydrogenolytic deprotection competed with saturation of the tetracyclic isochromenonaphthoimidazole core, often producing a complex mixture requiring preparative SFC purification.
A common failure mode observed on 50-mmol scale is the formation of a viscous gum during Boc cleavage if the reactor is not adequately swept with nitrogen prior to acid addition. Dissolved oxygen in the dioxane promotes oxidation of the imidazole NH, generating a colored dimer that precipitates as an amorphous solid difficult to filter. A continuous nitrogen sparge (0.5 vvm) for 10 minutes before TFA addition eliminates this issue entirely.
For couplings where the unprotected amine is required at the outset—for example, solid-phase anchoring to a 2-chlorotrityl chloride resin—the Boc-deprotected hydrochloride salt is lyophilized from 0.1 N HCl/acetonitrile (1:1) and stored over phosphorus pentoxide at −30 °C. When kept strictly anhydrous, the free-flowing powder loses less than 0.3% potency over 12 months by HPLC.
| Parameter | (2S,4S) target | (2R,4R) isomer | Test method |
|---|---|---|---|
| Retention time (min) | 14.3 | 15.8 | USP <621>, XSelect CSH C18, 50→95% MeCN/H₂O with 0.1% TFA, 30°C |
| Solubility in THF (mg/mL) | 78 (25°C) | 34 (25°C) | Gravimetric, saturated solution, 24 h equilibration |
| Coupling efficiency with HATU/DIPEA | 94% isolated | 71% isolated | Model dipeptide, 1.2 eq acid, DMF, 0°C→RT, 18 h |
| Epimerization t₁/₂ at pH 9.0, 25°C | 6.4 h | 1.8 h | CD spectroscopy, θ at 228 nm |
Process development groups evaluating the two diastereomers for kilogram-scale synthesis have reported that the (2R,4R) form requires significantly longer reaction times for the crucial HATU-mediated amide bond formation—often 36–48 h versus 18–24 h for the (2S,4S)—and yields a crude product that is darker in color and more difficult to crystallize without column chromatography. This difference is attributed to a less favorable presentation of the carboxylic acid coupling partner, as inferred from molecular mechanics (MMFF94) minimization of the respective pre-activation complexes. Consequently, the (2S,4S) diastereomer has become the preferred building block in published patent routes for macrocyclic NS3/4A inhibitors, where a single chromatography purification step is the maximum tolerated cost constraint.
The tetracyclic isochromenonaphthoimidazole core present in this intermediate introduces a subtle electronic deactivation at the terminal olefins when the imidazole NH is not adequately protected. In the presence of even trace moisture (0.2% water in DCM), the Hoveyda-Grubbs second-generation catalyst (5 mol%) exhibits a turnover frequency depressed by nearly 40%, as measured by ReactIR monitoring of the olefin stretch at 1650 cm⁻¹. This deactivation is reversible if the solvent is rigorously dried over activated 4Å molecular sieves (300°C activation, 4 h) prior to use. Yet a deeper incompatibility emerges when the methoxycarbonylvaline side chain is deprotected to the free amine prior to metathesis: the amine-poisoned ruthenium catalyst cannot be recovered, and ring closure fails entirely. This operational boundary demands that the fully protected compound be advanced through metathesis, where the Boc-pyrrolidine and methoxycarbonyl functionalities remain intact. Published procedures from related macrocyclic systems specify charging the catalyst in two portions, 3 mol% at t = 0 and an additional 2 mol% after 6 h, to achieve 92% conversion by 16 h at 40 °C in 0.01 M DCE.
In contrast to earlier intermediates that required high-dilution conditions (0.001 M) and produced oligomeric by-products, the preorganized conformation of this (2S,4S) diastereomer allows ring closure at a synthetically useful 0.02 M, a fivefold improvement in throughput for the cyclization vessel. This throughput gain was verified on a Corning Advanced-Flow G1 SiC reactor, where continuous-flow metathesis at 60°C (residence time 12 min) delivered 88% steady-state conversion without oligomer precipitation, a result unattainable with the (2R,4R) isomer due to its lower solubility.
For those integrating the compound into a convergent synthesis, the long-term storage specification calls for neat material to be kept under argon in amber glass vials at −20 °C ± 5 °C. Under these conditions, the purity loss is less than 0.5% per annum when monitored by HPLC at 254 nm. Pre-dried material exposed to relative humidity above 60% during weighing picks up 1.2% water within 15 minutes, which is sufficient to cause turbidity upon dissolving in anhydrous DMF for peptide couplings. A recommendation emerging from kilo-lab experience is to standardize all handling inside a glovebox purged to <5 ppm moisture, thereby eliminating a previously intractable batch-to-batch variability of ±7% in the metathesis conversion.
A second, often underappreciated, incompatibility involves base-catalyzed methanolysis of the methoxycarbonyl protecting group during preparative reverse-phase chromatography when ammonium bicarbonate-modified mobile phases are employed at pH 8.5. Fractions pooled over 4 h at ambient temperature show 1.8% methyl ester cleavage, forming the corresponding valine carboxylic acid impurity that co-elutes with the product. Substituting a volatile triethylammonium acetate buffer (pH 6.8) and cooling the fraction collector to 4°C eliminates this degradation, a finding codified in the internal monograph and shared with contract manufacturing organizations during technology transfer.
When this intermediate serves as a solution-phase fragment for appendage to resin-bound peptide scaffolds, the coupling protocol diverges from standard Fmoc-based strategies. The absence of a free carboxylic acid handle necessitates activation of the resin-loaded peptide’s N-terminus as a pentafluorophenyl ester prior to fragment condensation. On a 5-mmol scale (employing 2-chlorotrityl chloride resin, 1.2 mmol/g loading), coupling yields after 16 h exceed 90% only when the activated resin is pre-swollen in N-methyl-2-pyrrolidone for 30 min and the fragment is added as a 0.15 M solution in DCM/NMP (4:1 v/v). Alternative activation via HBTU/HOBt in the presence of the fragment results in substantial (>30%) guanidinylation of the imidazole ring, as detected by LCMS [M+H]+ + 42 Da. This side reaction is specific to the fused imidazole system and is not observed with simpler 2-phenylimidazole models, underscoring the atypical nucleophilic character of the NH group within the extended π-system of the isochromenonaphthoimidazole core.
The methoxymethyl ether on the pyrrolidine ring, while seemingly innocuous, plays a decisive role during acidolytic cleavage from the resin. When the cleavage cocktail comprising 95% TFA, 2.5% water, and 2.5% triisopropylsilane is applied, the methoxymethyl group undergoes partial (~12%) cleavage only if the reaction time extends beyond 4 h. Controlled cleavage at 3 h delivers the product with <1% des-methoxymethyl impurity, which is within the specification of <2.0% for this related substance per ICH Q3A. Analogs lacking the methoxymethyl substitution, such as the simple 4-methylpyrrolidine variant, exhibit poorer solubility in the coupling solvent mixture (<12 mg/mL in DCM/NMP) and require double coupling cycles that inflate the process cycle time by 60%.
| Test | Acceptance criterion | Method |
|---|---|---|
| Appearance | White to slightly cream powder | Visual, USP <631> |
| Assay (anhydrous basis) | ≥98.0% | HPLC, USP <621>, external standard |
| Single impurity | ≤1.0% | HPLC, same as assay, area normalization |
| Diastereomeric impurity (2R,4S) | ≤0.5% | Chiral HPLC, USP <621> |
| Water content | ≤0.5% w/w | Karl Fischer, USP <921> Method Ic |
| Residual solvents: DCM | ≤600 ppm | GC-HS, USP <467> Procedure A |
| Residual solvents: DMF | ≤880 ppm | GC-HS, USP <467> Procedure A |
| Heavy metals | ≤10 ppm | USP <231> (Method II) |
| Residue on ignition | ≤0.1% | USP <281> |
| Storage | −25 °C to −15 °C, desiccated, under argon, protected from light | Upon receipt |
In production campaigns that integrated this fragment as an advanced intermediate, a decision to bypass preparative HPLC in favor of direct anti-solvent precipitation from THF/heptane resulted in a significant elevation of the single unknown impurity at relative retention time 1.31 from 0.4% to 2.8%. Subsequent structure elucidation by high-resolution mass spectrometry (Q-TOF, 100,000 FWHM) and 1H-13C HSQC identified the impurity as an N-formyl adduct derived from the imidazole NH reacting with residual formamide generated through solvent decomposition during extended rotary evaporation above 45 °C. Implementing a strict jacket temperature limit of 35 °C during concentration and substituting heptane with methylcyclohexane for the final precipitation step reduced the N-formyl species to <0.10%. This thermal sensitivity is unique to intermediates bearing the intact imidazole NH and does not affect the methylated imidazole congener that is formed later in the route, providing a clear differentiator from downstream products.
The methoxycarbonyl protecting group itself can undergo unwanted aminolysis if the free amine of the next coupling partner is present in excess for prolonged periods. In concentrated DMF solution (0.3 M, 25 °C, 24 h) with 1.5 equivalents of pyrrolidine as a model nucleophile, transamidation proceeds to 4.2%, generating a methyl carbamate impurity that is difficult to purge by crystallization. This incompatibility with strongly nucleophilic secondary amines requires that fragment couplings be performed with the amine component as the limiting reagent (0.95 eq relative to activated acid) and that the reaction be quenched promptly upon reaching >98% conversion as tracked by HPLC.